116 related articles for article (PubMed ID: 28223773)
1. Erratum: A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum].
Clin Ophthalmol; 2017; 11():303. PubMed ID: 28223773
[TBL] [Abstract][Full Text] [Related]
2. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis.
Singh RP; Srivastava SK; Ehlers JP; Silva FQ; Bedi R; Schachat AP; Kaiser PK
Clin Ophthalmol; 2015; 9():1759-66. PubMed ID: 26445522
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H; Shah CP; Weber M; Heier JS
Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
[TBL] [Abstract][Full Text] [Related]
4. Initial utilization of aflibercept in exudative age-related macular degeneration.
Cho H; Weber ML; Shah CP; Heier JS
Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
[TBL] [Abstract][Full Text] [Related]
5. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
Chan CK; Jain A; Sadda S; Varshney N
Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
Narayan DS; Muecke J
Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
[TBL] [Abstract][Full Text] [Related]
7. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
8. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
11. A 24-Month Evaluation of Aflibercept for Wet Age-Related Macular Degeneration in Patients Previously Receiving Ranibizumab or Bevacizumab.
Silva FQ; Srivastava S; Ehlers JP; Li A; Bedi R; Schachat AP; Singh RP
Ophthalmol Retina; 2017; 1(2):111-117. PubMed ID: 31047267
[TBL] [Abstract][Full Text] [Related]
12. Erratum: Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum].
Clin Ophthalmol; 2017; 11():355. PubMed ID: 28243059
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.
Lazzeri S; Ripandelli G; Sartini MS; Parravano M; Varano M; Nardi M; Di Desidero T; Orlandi P; Bocci G
Angiogenesis; 2015 Oct; 18(4):397-432. PubMed ID: 26346237
[TBL] [Abstract][Full Text] [Related]
15. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
[TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability.
Hata M; Oishi A; Tsujikawa A; Yamashiro K; Miyake M; Ooto S; Tamura H; Nakanishi H; Takahashi A; Yoshikawa M; Yoshimura N
Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):7874-80. PubMed ID: 25395483
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
Hall LB; Zebardast N; Huang JJ; Adelman RA
J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
[TBL] [Abstract][Full Text] [Related]
20. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
